Combination chemotherapy in advanced gastrointestinal malignancy.
This study compares two combinations of drugs with proven activity in gastrointestinal malignancy. The drugs utilized are 5-fluorouracil (5FU), mitomycin C (Mito C), and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU). All 57 patients received 5FU 25 mg/kg as a 24-hour infusion for 5 days every 4 weeks. One group received Mito C 20 mg/m2 IV bolus every 8 weeks. The second group received MeCCNU 150 mg/m2 orally every 8 weeks. These combinations are tolerable, and the toxicities are acceptable. The response to 5FU/Mito C is more efficacious at 47% than 5FU/MeCCNU at 25% in the treatment of evaluable patients with colorectal malignancy.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral / Q000295:instrumentation; D008937:Mitomycins / Q000008:administration & dosage; D010859:Pigmentation Disorders / Q000139:chemically induced; D012673:Semustine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D008937:Mitomycins; D012673:Semustine; D005472:Fluorouracil